Posted by Michael Wonder on 30 Jun 2021
ICER to assess treatment for type 2 diabetes
30 June 2021 - Report will be subject of New England CEPAC meeting in January 2022; draft scoping document open to public comment until 21 July 2021.
The ICER announced today that it will assess the comparative clinical effectiveness and value of tirzepatide (Eli Lilly) for the treatment of type 2 diabetes mellitus.
